August 27, 2012
Today Idenix placed a clinical hold on IDX19368, a nucleotide polymerase inhibitor - (no patients have been exposed to IDX19368). The FDA verbally informed Idenix of concerns related to serious heart issues seen in
Bristol-Myers nucleotide polymerase inhibitor BMS-986094. On August 23 Bristol-Myers discontinued the phase II trial after one patient died, also nine patients were hospitalized and two remained hospitalized. As of yet, Bristol-Myers has not established a definitive relation between BMS-986094 and heart and kidney toxicity.
Recently IDX184 which is another experimental nucleotide polymerase inhibitor from Idenix Pharmaceuticals, was put
on partial hold because of the potential for heart damage. In today's press release (see below) the company stated under the request of the FDA patients who took part in the IDX184 trial are undergoing cardiac testing.
As part of the partial clinical hold placed on IDX184, the FDA has requested additional cardiac testing of patients in the ongoing phase IIb clinical trial of IDX184. More than 50 patients have been scheduled for echocardiograms, and the Company is on track to submit these data to the FDA in the coming weeks. To date, echocardiograms have been performed on a small number of these patients, and the results are normal.
FDA places clinical
hold on Idenix Pharmaceuticals’ hepatitis C drug IDX19368
Last Updated:August 27, 2012 12:25
Source
Idenix Pharmaceuticals' shares fell as much as 12 percent on Monday on news
that the FDA placed a clinical hold on its hepatitis C compound IDX19368 due to
cardiac-related concerns about Bristol-Myers Squibb's BMS-986094, which belongs
to the same nucleotide polymerase inhibitor drug class. The company also said
the FDA had requested additional cardiac testing of patients in an ongoing Phase
IIb trial of its other hepatitis C treatment, IDX184, as part of a recent
partial clinical hold on
the compound stemming from the BMS-986094 concerns, and that it expects to
submit the data in the coming weeks.
CEO Ron Renaud stated that "based on our discussions with the FDA, we
understand the clinical hold [on IDX19368] is a precautionary decision." Idenix
confirmed that no patients were exposed to IDX19368 thus far. Last week,
Bristol-Myers Squibb reported that it would
halt development
of its therapy after one patient died and eight others were hospitalised in
clinical trials.
Renaud explained that while "both IDX184 and IDX19368 fall into the same
broader class of NS5B inhibitors, and share the same active metabolite as
BMS-986094,…there are many attributes of our compounds, particularly the prodrug
approach, that we believe favourably differentiate the toxicity profiles" from
BMS-986094. He added that Bristol-Myers Squibb "agreed to share relevant
information on BMS-986094 with us and hope this helps us to resolve this issue
quickly."
Commenting on the news, Brean Murray Carret & Co. analyst Brian Skorney
remarked, "I don’t think it takes both Idenix drugs off the table, but it does
slow them down."
Idenix Drops After FDA Places Hold on Hepatitis C Drug - (Bloomberg)
Idenix Provides Update on IDX19368 Development Program - (GlobeNewswire)
Idenix: FDA Places Hepatitis C Treatment on Clinical Hold
- (Morningstar)
Idenix Hep C Fortunes Fade Fast -
(TheStreet)
Press Release - Idenix Provides Update on IDX19368 Development Program
IDX19368, for Which Idenix Has Submitted an IND Application, Has Been Placed on Clinical Hold by FDA
CAMBRIDGE, Mass.,
Aug. 27, 2012 (GLOBE NEWSWIRE) --
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company received verbal notice from the
U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on IDX19368, the Company's next-generation nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV) infection. This news follows an announcement that Idenix made on
August 16, 2012 related to a partial clinical hold placed on IDX184, the Company's lead nucleotide polymerase inhibitor also under development for the treatment of HCV.
The
FDA verbally informed Idenix that it placed IDX19368 on clinical hold due to concerns related to the serious cardiac-related adverse events reported for HCV patients treated with BMS-986094, a nucleotide polymerase inhibitor previously under development by Bristol-Myers Squibb Company. To date, no patients have been exposed to IDX19368.
"Based on our discussions with the
FDA, we understand the clinical hold is a precautionary decision made by the
FDA in light of the adverse events seen with BMS-986094," said
Ron Renaud, President and CEO. "Both IDX184 and IDX19368 fall into the same broader class of NS5B inhibitors, and share the same active metabolite as BMS-986094. However, there are many attributes of our compounds, particularly the prodrug approach, that we believe favorably differentiate the toxicity profiles from that of BMS-986094. We recently learned that Bristol-Myers Squibb has agreed to share relevant information on BMS-986094 with us and hope this helps us to resolve this issue quickly."
As part of the partial clinical hold placed on IDX184, the
FDA has requested additional cardiac testing of patients in the ongoing phase IIb clinical trial of IDX184. More than 50 patients have been scheduled for echocardiograms, and the Company is on track to submit these data to the
FDA in the coming weeks. To date, echocardiograms have been performed on a small number of these patients, and the results are normal. Idenix's primary concern is patient safety and it will work diligently to expedite this review process and continue its discussions with the
FDA with the goal of further advancing its drug candidates, IDX184 and IDX19368, in clinical development.
ABOUT IDX19368
IDX19368 is an unpartnered liver-targeted nucleotide prodrug of 2'-methyl guanosine and was selected from a prodrug series of approximately 350 compounds. It has shown high triphosphate levels
in vivo, with a low potential for drug-drug interactions.
In the third quarter of 2012, Idenix submitted an investigational new drug (IND) application for IDX19368 with plans to initiate clinical trials in the third quarter of 2012. However, these clinical trials will not commence until the
FDA removes the clinical hold.
ABOUT IDX184
IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2'-methyl guanosine, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing.
In
July 2012, an independent data safety monitoring board reviewed the safety data for this study and confirmed that the side effect profile of IDX184 combined with PegIFN/RBV is consistent with that of PegIFN/RBV alone.
The
FDA placed IDX184 on partial clinical hold as reported on
August 16, 2012. In previous clinical trials as well as the ongoing phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV), there has been no evidence to date of cardiotoxicity in patients dosed with IDX184 with PegIFN/RBV beyond that seen with PegIFN/RBV alone. There are currently no patients receiving IDX184 worldwide.
ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in
Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to
www.idenix.com.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the Company's development of drug candidates and its future business performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "intends," "will," and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the Company's potential pipeline candidates, including any expressed or implied statements regarding the Company's ability to continue clinical development of IDX184 and IDX19368, the efficacy and safety of IDX184 and IDX19368; the likelihood and success of any future clinical trial involving IDX184 and IDX19368 and the successful development of these compounds. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the Company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates and clinical trials of compounds under development by other companies; changes in the Company's business plan or objectives; competition in general; and the Company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in the Company's annual report on Form 10-K for the year ended
December 31, 2011 and the quarterly report on Form 10-Q for the quarter ended
June 30, 2012, each as filed with the
Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the Company files with the
SEC.
All forward-looking statements reflect the Company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the Company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company's estimates change.
CONTACT: Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Daniella Beckman (617) 224-4471 (investors)
Source: Idenix Pharmaceuticals
News Provided by Acquire Media
